Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SAVA 
Cassava Sciences Inc (SAVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SAVA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -41.59% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.54M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta -2.02 | 52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 |
52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -59.03% | Return on Equity (TTM) -70.6% |
Valuation
Trailing PE - | Forward PE 151.52 | Enterprise Value -35631025 | Price to Sales(TTM) - |
Enterprise Value -35631025 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.26 | Shares Outstanding 48307900 | Shares Floating 43475174 |
Shares Outstanding 48307900 | Shares Floating 43475174 | ||
Percent Insiders 12.79 | Percent Institutions 33.05 |
Upturn AI SWOT
Cassava Sciences Inc
Company Overview
History and Background
Cassava Sciences, Inc., founded in 1998, is a clinical-stage biotechnology company focused on developing drugs for neurodegenerative diseases, particularly Alzheimer's disease.
Core Business Areas
- Drug Development: Focuses on developing and commercializing therapeutics for Alzheimer's disease.
Leadership and Structure
Remi Barbier is the President and CEO. The company has a standard organizational structure with departments focused on research, clinical development, and administration.
Top Products and Market Share
Key Offerings
- Simufilam: An investigational drug for Alzheimer's disease. It aims to restore the normal shape and function of altered filamin A, a scaffolding protein, in the brain. Simufilam is currently in clinical trials. The company faces heavy competition from companies like Eli Lilly (LLY) with Donanemab.
Market Dynamics
Industry Overview
The Alzheimer's disease treatment market is a large and growing market due to the increasing aging population. It's characterized by high unmet needs and intense competition among pharmaceutical companies.
Positioning
Cassava Sciences is a smaller player in the Alzheimer's drug development space, focusing on a novel approach with Simufilam. Its competitive advantage lies in its unique mechanism of action, if proven effective.
Total Addressable Market (TAM)
The global Alzheimer's disease market is expected to reach hundreds of billions of dollars. Cassava Sciences' positioning depends on the success of Simufilam; successful trials could lead to significant market penetration.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action (Simufilam)
- Potential for disease-modifying treatment
- Focus on a significant unmet need
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a single drug candidate (Simufilam)
- Controversies and allegations surrounding clinical trial data
Opportunities
- Positive clinical trial results could lead to rapid market adoption
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other Alzheimer's drugs
- Continued scrutiny and allegations surrounding clinical trial data
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ESAI
Competitive Landscape
Cassava Sciences faces intense competition from larger, more established pharmaceutical companies with more resources and approved products. Their competitive advantage relies on Simufilam's novel approach, if validated.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is non-existent due to pre-revenue stage.
Future Projections: Future growth is entirely dependent on the successful development and commercialization of Simufilam. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: The main initiative is progressing Simufilam through clinical trials.
Summary
Cassava Sciences is a high-risk, high-reward investment. Its success hinges on the clinical success of Simufilam. The company faces intense competition and has been subject to scrutiny, necessitating careful monitoring of clinical trial data and regulatory developments. Continued progress in clinical trials will result in a more positive outlook, while setbacks could significantly impact its value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Analyst Reports, Press Releases
- ClinicalTrials.gov
Disclaimers:
The analysis provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are based on projections and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cassava Sciences Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2000-07-14 | CEO, President & Director Mr. Richard Jon Barry | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://www.cassavasciences.com |
Full time employees 30 | Website https://www.cassavasciences.com | ||
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.